Lexicon Genetics Incorporated (LEXG) to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
11/23/2009 9:32:21 AM
More...
|
Lexicon Genetics Incorporated (LEXG) Initiates Phase 2 Clinical Trial of LX2931 in Patients With Rheumatoid Arthritis
8/4/2009 7:58:07 AM
More...
|
Lexicon Genetics Incorporated (LEXG) Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
11/12/2007 8:05:59 AM
More...
|
Lexicon Genetics Incorporated (LEXG) to Present at the Biotechnology Industry Organization (BIO) 2007 International Convention
5/7/2007 1:50:26 PM
More...
|
Lexicon Genetics Incorporated (LEXG) Changes Name to Lexicon Pharmaceuticals as Drug Development Pipeline Progresses
4/26/2007 12:07:01 PM
More...
|
Lexicon Genetics Incorporated (LEXG) Advances LX1031 for Irritable Bowel Syndrome Into Phase 1b Clinical Trial
4/24/2007 12:31:28 PM
More...
|
Lexicon Genetics Incorporated (LEXG) to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4/23/2007 11:59:44 AM
More...
|
Lexicon Genetics Incorporated (LEXG) to Report First Quarter 2007 Financial Results on May 1, 2007; Conference Call and Webcast to Follow
4/13/2007 11:42:28 AM
More...
|
Lexicon Genetics Incorporated (LEXG) Appoints Tamar Howson Executive Vice President of Business Development
3/21/2007 1:06:33 PM
More...
|
Lexicon Genetics Incorporated (LEXG) Elects Kathleen Wiltsey to Board of Directors
2/28/2007 11:06:36 AM
More...
|
|